Загрузка...
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection
Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (pj) can lead to serious health consequences in patients with an immunocompromised system. Trimethoprim (TMP), used as first-line therapy in combination with sulfamethoxazole, is a selective but only moderately potent pj dihydrofolate red...
Сохранить в:
| Опубликовано в: : | Bioorg Med Chem Lett |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6588427/ https://ncbi.nlm.nih.gov/pubmed/31176699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2019.06.004 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|